Wednesday, 24 April 2019

Sun Pharma’s Aggrenox gets USFDA nod

24 August 2018 | News

This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox (Aspirin/Dipyridamole). Aggrenox and its generics are estimated to have US sales of ~$230mn in the US

Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox.

 Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.

Aggrenox and its generics are estimated to have US sales of approximately $230mn in the US and with the lower competition, Sun pharma expect to make $8-10mn/annum from this drug.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account